B
Bullisch
Bullisch · 25%ASND
$234.42
Szenariopreis
$238.900
+4.659 (+1.95%)Zum Schluss
Loading chart…
- Hoch
- 240.210
- Eröffnung
- 236.000
- Volumengewichteter Durchschnittskurs
- 238.20
- Volumen
- 662.12K
- Marktkap.
- 7.73B
- Tief
- 235.500
- Umsatz
- 157.72M
- EV/EBITDA, TTM
- 11.33
Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.
KI-Analyse of Ascendis Pharma A/S (ASND)
HaltenAscendis Pharma (ASND) is currently a hold. The stock is trading at $225.25, which is below the analyst price target range of $273 to $312, indicating potential upside. However, the RSI is at 43.23, suggesting the stock is nearing oversold territory, but not yet a strong buy signal. The recent positive regulatory news for TransCon CNP could drive future growth, but insider selling has increased by 565.41%, indicating potential caution from insiders. The main risk is the recent 5-day change of -1.74%, reflecting short-term volatility.
Analystenbewertungen (6)
+15.98% Aufwärtspotenzial
Kaufen
5 Kaufen
1 Halten
0 Verkaufen
Aktuell: 238.90
Tief
240.00
Durchschnitt
277.08
Hoch
342.00
Raymond James
Überdurchschnittlich
$287
2026-09-15
Raymond James
2026-09-15
Kursziel
$287
Überdurchschnittlich
Oppenheimer
Überdurchschnittlich
$312
2026-09-02
Oppenheimer
2026-09-02
Kursziel
$312
Überdurchschnittlich
Morgan Stanley
Übergewichten
$273
2026-09-01
Morgan Stanley
2026-09-01
Kursziel
$273
Übergewichten
H.C. Wainwright
Kaufen
$344
2026-08-31
H.C. Wainwright
2026-08-31
Kursziel
$344
Kaufen
BofA
Kaufen
$304
2026-08-31
BofA
2026-08-31
Kursziel
$304
Kaufen
Bewertungskennzahlen
Das aktuelle erwartete KGV von Ascendis Pharma A/S (ASND) beträgt 19.84, verglichen mit dem 5-Jahres-Durchschnitt von 3.37.
Alphio-AI-Kursszenarien für ASND
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die ASND halten
Event-Zeitleiste
News
9.010-16stocktwitsAscendis Receives Positive Regulatory Opinion for Drug
8.510-16NewsfilterAscendis Pharma Receives Positive Opinion from EU for TransCon CNP
8.009-15NASDAQ.COMAscendis Pharma Authorizes $400 Million Share Repurchase Program
9.009-09Yahoo FinanceAscendis Pharma Reports Week 52 Data on TransCon CNP Treatment
8.509-08NASDAQ.COMAscendis Pharma Unveils New Data at ESPE Congress
ASND FAQ – beantwortet von Alphio AI
Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Ascendis Pharma (ASND) is currently a hold. The stock is trading at $225.25, which is below the analyst price target range of $273 to $312, indicating potential upside. However, the RSI is at 43.23, suggesting the stock is nearing oversold territory, but not yet a strong buy signal. The recent positive regulatory news for TransCon CNP could drive future growth, but insider selling has increased by 565.41%, indicating potential caution from insiders. The main risk is the recent 5-day change of -1.74%, reflecting short-term volatility.
6 analysts cover ASND: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 277.08.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.